Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy
HemaSphere · 2026-06 · 10 (6)
DOI: 10.1002/hem3.70384 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 29.05.2026. Verfasst von Austin Kulasekararaj und 31 weiteren Autor:innen. Beteiligte Einrichtung: King's College Hospital NHS London UK. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti‐C5 often experience extravascular hemolysis with anemia. Iptacopan, the first oral proximal complement inhibitor targeting factor B, has shown efficacy and safety in PNH patients. APPULSE‐PNH (NCT05630001), a phase 3b, single‑arm, open‐label trial, enrolled adult patients with PNH and hemoglobin ≥10 g/dL on stable anti‐C5 for ≥6 months. Patients switched to iptacopan monotherapy (200 mg twice daily; 24 weeks). Primary endpoint: mean hemoglobin change from baseline across four visits (Days 126–168). At baseline, 57.7% of patients had elevated absolute reticulocyte counts (ARCs; above ULN = 123 × 10 9 /L) and 50% had C3 deposition on red blood cells (RBCs) >10%, indicative of extravascular hemolysis. There was a statistically significant increase in hemoglobin during the trial; adjusted mean change from baseline (95% CI) was +2.0 g/dL (1.7–2.3) overall, and in patients with baseline hemoglobin
Autor:innen und Institutionen
- King's College Hospital NHS London UK.
- National Institute for Health and Care Research and Wellcome King's Research Facility London UK.
- The Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (UK, Italy and the Netherlands) Barcelona Spain.
- French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Paris France.
- Hospital Clínic of Barcelona Barcelona Spain.
- USC Norris Cancer Center, Keck-USC School of Medicine Los Angeles California USA.
ORCID-Profile: Austin Kulasekararaj, Anna Gaya
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Kulasekararaj, A., de Fontbrune, F. S., Gaya, A., Weitz, I., Kuter, D. J., Patel, B. J., Araten, D. J., Singh, A., Jang, J. H., Kelly, R. J., Di Bona, E., Loschi, M., Pullarkat, V., Schubert, J., Notaro, R., Yenerel, M. N., Beckman, J., Blin, N., Murakhovskaya, I., …, & Risitano, A. M. (2026). Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70384
Vancouver
Kulasekararaj A, de Fontbrune FS, Gaya A, Weitz I, Kuter DJ, Patel BJ, et al. Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy. HemaSphere. 2026;10(6). doi:10.1002/hem3.70384
BibTeX
@article{Kulasekararaj2026,
author = {Kulasekararaj, Austin and de Fontbrune, Flore S and Gaya, Anna and Weitz, Ilene and Kuter, David J and Patel, Bhumika J and Araten, David J and Singh, Abhay and Jang, Jun H and Kelly, Richard J and Di Bona, Eros and Loschi, Michael and Pullarkat, Vinod and Schubert, Jörg and Notaro, Rosario and Yenerel, Mustafa N and Beckman, Joan and Blin, Nicolas and Murakhovskaya, Irina and Panse, Jens and Roman, Eloy and Röth, Alexander and Schrezenmeier, Hubert and Tantravahi, Srinivas and de Latour, Régis P and Mahajan, Navin and Monaco, Luca and Ding, Tao and Lawniczek, Tomasz and Ferber, Philippe and Dahlke, Marion and Risitano, Antonio M},
title = {Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {6},
doi = {10.1002/hem3.70384}
}
EUVIMED